Undisclosed B7-H3xNKG2D NKE / Xencor - LARVOL DELTA

Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306 (Businesswire) - "Preclinical Data Presentations: New data from four preclinical-stage programs, including Xencor’s IL-12-Fc cytokine program, PD-L1 x CD28 bispecific antibody program, TGFβR2 bispecific antibody platform, and bispecific NK cell engager platform, will also be presented at the SITC Annual Meeting."

Preclinical • Oncology

Natural Killer cell engagers activate innate and adaptive immunity and show synergy with proinflammatory cytokines (SITC 2021) - "Conclusions XmAb bispecific NKEs engineered to engage innate and adaptive immunity show encouraging tumor cell killing activity and synergistic cytotoxicity in combination with proinflammatory cytokines. These data have identified several promising candidate NKEs for future in vivo efficacy studies in mouse tumor models expressing B7H3."

IO biomarker • Oncology • CD276 • IL15 • NKG2D